Two of BeyondSpring’s (NASDAQ:BYSI) abstracts about its lead asset, Plinabulin, were accepted for publication in the proceedings of this year’s ASCO annual meeting May 31 to June 4 in Chicago. The data, derived from...
MacroGenics’ (NASDAQ:MGNX) Phase 3 trial of margetuximab met its first sequential primary endpoint of progression-free survival (PFS) in patients with HER2-positive metastatic breast cancer. The median PFS of patients...
Cue Biopharma’s (NASDAQ:CUE) IND for CUE-101, an immuno-oncology candidate for human papilloma virus (HPV)-associated cancers, had been accepted by the FDA. The majority of HPV-associated cancers are caused by the HPV16...
Rigel Pharmaceuticals (NASDAQ:RIGL) enrolled the first patient in its pivotal Phase 3 trial of fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia (AIHA).
Ceapro’s (TSXV:CZO) two bioprocessing plants in Alberta received a site license from the Health Canada Natural and Non-Prescription Health Products Directorate, which enables the company to fabricate, package, label...
Principia Biopharma (NASDAQ:PRNB) has dosed the first patient in its Phase 2b clinical trial of SAR442168 in patients with relapsing multiple sclerosis (MS). Neuroinflammation and an increase in the number of B cells in...
Athersys’ (NASDAQ:ATHX) MultiStem cell therapy for the treatment of acute respiratory distress syndrome (ARDS) has received FDA fast track designation. ARDS is a widespread inflammation of the lungs that can be...
MeiraGTx (NASDAQ:MGTX) reported that AAV-RPE65, its investigational gene therapy for the treatment of retinal dystrophy, met the primary endpoint of safety and tolerability in a Phase 1/2 study, as well as demonstrated...
Homology Medicines’ (NASDAQ:FIXX) received FDA fast track designation for HMI-102, a gene therapy for the treatment of adults with phenylketonuria (PKU), a rare genetic disease affecting metabolism. Individuals with PKU...